Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
Showing public results only.
Agroz has a real Malaysian CEA business and fast disclosed H1 2025 revenue growth, but AGRZ is a limited-disclosure microcap until it files FY2025 annual results, collects receivables and proves cash conversion.
OpenAdvanced Biomed has historical cancer-diagnostics technology, but the latest filings show no product revenue, a reverse split, a short-term loan, a subsidiary divestiture, and an April 2026 pivot into AI.
Open20/20 Biolabs has a real OneTest cancer-screening revenue base and a fresh Nasdaq listing, but FY2025 losses, negative cash flow, Streeterville financing and resale overhang keep AIDX in a high-risk coverage bucket.
OpenAI Infrastructure Acquisition Corp. is a newly public SPAC with $140.5 million in trust, $1.1 million of cash outside trust, no operating revenue, no announced target and an April 6, 2027 deadline. The current thesis is trust math, sponsor incentives and futur
OpenSenmiao Technology is a very high risk China ride-hailing auto-services microcap. The filings show a small post-disposal operating base, continuing losses, material weaknesses, Nasdaq compliance pressure and potentially heavy dilution mechanics.
OpenAllied still has HyperX Arena Las Vegas, Z-Tech mobile games, and a balance-sheet cushion, but the current thesis is about the late 10-K, Nasdaq delisting risk, reverse-split vote, Knighted settlement, and whether revenue can ever catch the cost base.
OpenAimei Health is no longer a healthcare-search story. It is a high-risk de-SPAC watch where a small remaining SPAC trust is trying to close a $1.5 billion all-share United Hydrogen transaction.
OpenAEXA is not a business yet. It is a NYSE-listed SPAC with $351.4 million in trust, $0.3 million of cash outside trust, no selected target as of March 31, 2026, and public shareholder economics that turn on redemption value, sponsor incentives and the future de
OpenActivate Energy has no wells, no operating revenue, and no target yet. The source-backed story is a $230.6 million trust account, a December 2027 deal clock, oil-and-gas sponsor ambition, and a structure where Class A shares and warrants carry very different r
OpenAditxt's filings show a precommercial health-innovation platform with immune, diagnostic, infectious-disease, women's-health, and proteomics ambitions, but the source-backed decision point is Nasdaq survival, cash, dilution, and whether any program can outrun
OpenAdaptive's clonoSEQ MRD business is finally showing scale, but the proof gate is whether test volume, reimbursement, pharma milestones, and operating leverage can absorb cash burn and the OrbiMed revenue-interest obligation.
OpenAmerican Drive Acquisition Company gives investors a documented SPAC trust, a defense/logistics/technology/AI search mandate, and no operating target yet. The useful question is whether the eventual deal beats the promote, warrants, redemption risk, and deadli
OpenAclarion has a distinctive MRS-based spine diagnostic workflow, a stronger post-financing cash balance, and visible CLARITY and payer proof gates, but FY2025 revenue was only $75,730 and the company still has to convert Nociscan from clinical promise into reim
OpenACCESS Newswire has refocused around press release distribution, media monitoring, IR websites, events, and subscriptions after selling its Compliance business. The hook is improving ARR and retention; the risk is that the remaining company is still tiny, comp
OpenACAA gives investors a real trust account, a health-and-technology sponsor story, and almost no operating company to analyze. The question is whether that blank check becomes a disciplined de-SPAC or another dilution machine.
OpenAbbott's Medical Devices engine, led by diabetes care, is doing the heavy lifting while Nutrition weakens and the Exact Sciences acquisition adds cancer-diagnostics upside, debt, and integration risk.
OpenAcco Group is not ACCO Brands. It is a Hong Kong and Singapore corporate-services microcap with US$4.9 million of FY2025 revenue, positive net income, an October 2025 Nasdaq IPO, and a January 2026 vote that approved a dual-class structure. The business is rea
OpenOfficial-source baseline for Abony Acquisition Corp. I using SEC submissions, SEC XBRL companyfacts, the FY2025 10-K, Q1 FY2026 10-Q, final IPO prospectus, and IPO-related 8-Ks.
OpenOfficial-source baseline for Armada Acquisition Corp. III using SEC submissions, SEC XBRL companyfacts, the FY2025 10-K, Q1 FY2026 10-Q, final IPO prospectus, and IPO-related 8-Ks.
OpenOfficial-source baseline for Artius II Acquisition Inc. using SEC submissions, SEC companyfacts, the FY2025 10-K, Q1 FY2026 10-Q, and final IPO prospectus.
Open